News & Events

HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.

Read More

HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the fourth quarter and year ended December 31, 2016.

Read More

HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU

TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.

The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic assay intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC). The assay may be used to aid in the identification of patients eligible for treatment with ALK-targeted therapeutics, such as crizotinib, and is automated on the HTG EdgeSeq system using a next-generation sequencer for detection.

Read More

HTG Molecular Diagnostics to Hold 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 23, 2017

TUCSON, Ariz., March 21, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2016 fourth quarter and full year financial results after market close on Thursday, March 23, 2017. Company management will host an investment-community conference call beginning at 5:00pm Eastern Time on Thursday, March 23 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics’ & QIAGEN Scientific Symposium

This no-fee Symposium brings together key molecular and pharma professionals for the opportunity to network, discuss noteworthy and trending topics and exchange information in the fields of immuno-oncology and companion diagnostics.

Read More

HTG Molecular Diagnostics Appoints New Chair of the Board of Directors

TUCSON, Ariz., March 07, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the Chair of the company’s board of directors.

Read More

HTG Molecular Diagnostics Unveils New Direct-Target Sequencing Chemistry to Launch in First Quarter 2017

TUCSON, Ariz., Feb. 27, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM)(“HTG”), a provider of instruments, reagents and services for molecular profiling applications announced that its new direct-target sequencing chemistry will be available in the company’s VERI/O laboratory as a service offering beginning in the first quarter of 2017. The new chemistry is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company’s current HTG EdgeSeq chemistry applications. The initial panel planned for the VERI/O laboratory will detect common mutations in the EGFR, KRAS and BRAF genes for retrospective research studies especially from small and difficult samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue.

Read More

HTG Molecular Diagnostics Completes Module Three Filing for HTG EdgeSeq ALKPlus Assay PMA

TUCSON, Ariz., Jan. 05, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced that it has submitted to the FDA the third of four expected modules for the Company’s Pre-Market Approval (PMA) application for the HTG EdgeSeq ALKPlus Assay to be used as a companion diagnostic for Crizotinib.

Read More

HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics

TUCSON, Ariz., and VENLO, the Netherlands, Nov. 16, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt Stock Exchange:QIA); “QIAGEN”), announced a Master Assay Development, Commercialization and Manufacturing Agreement (“Agreement”). This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology. Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock.

Read More

HTG Molecular Diagnostics Reports Third Quarter 2016 Results

TUCSON, Ariz., Nov. 14, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and nine month periods ended September 30, 2016.

Read More

HTG Molecular Diagnostics to Hold 2016 Third Quarter Financial Results Conference Call on November 14, 2016

TUCSON, Ariz., Nov. 03, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 third quarter financial results after market close on Monday, November 14, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, November 14 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

TUCSON, Ariz., Nov. 02, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016 in New York City.

Read More